Clinical Trial Detail

NCT ID NCT01927744
Title Study of Chemotherapy With Cisplatin/CarboplatinAstellas Pharma Inc, OSI Pharmaceuticals, Kadoorie Foundation, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

oral squamous cell carcinoma

Therapies

Docetaxel + Erlotinib

Cisplatin

Docetaxel

Carboplatin

Age Groups: adult

No variant requirements are available.